Meeting
2021 ASCO Annual Meeting
First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report.
Authors
José Antonio Gonzalez
Hospital de la Santa Creu i Sant Pau, Surgery Department, Barcelona, Spain
José Antonio Gonzalez , Ana Sebio , Paula Cerdà , Francesc Cano , José Antonio Tornero , Luc Marti , Jaume Mora , Lucas Krauel , Antonio Lopez-Pousa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04619056
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 11554)
DOI
10.1200/JCO.2021.39.15_suppl.11554
Abstract #
11554
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2021 ASCO Annual Meeting
Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).
First Author: Jose Luis Perez-Gracia
Poster
2016 Gastrointestinal Cancers Symposium
A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
First Author: Teresa Macarulla
Poster
2024 ASCO Annual Meeting
Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.
First Author: Miguel Angel Villalona-Calero